Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|November 21, 2022
Dr. Lowentritt discusses phase 3 SPOTLIGHT trial on new PSMA-PET tool
Author(s)Urology Times staff
"The idea that we may have reliable and consistently interpretable tests for these patients is exciting for the future," says Benjamin Lowentritt, MD, FACS.
Advertisement
In this interview, Benjamin Lowentritt, MD, FACS, recaps key findings from the phase 3 SPOTLIGHT trial data that were presented at the 2022 ASTRO Annual Meeting. He is currently a practicing urologist at Chesapeake Urology in Baltimore, Maryland.
Advertisement
Related to this article
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Variation in PSMA PET Adoption for Prostate Cancer Care
3
FDA grants 510(k) clearance to OpenFlo urinary catheter
4
FDA grants fast track designation to VIR-5500 for mCRPC
5